Unlocking Insights
in Lung Cancer
Lung Cancer Dataset Insights
Our dataset° provides valuable insights into lung cancer, including but not limited to:
+7400
Estimated N Lung Carcinoma Patients
71.2%
% 1 year survival
70.71
Mean age at diagnosis
Top regimens used
- Pembrolizumab
- Pemetrexed, Carboplatin, Pembrolizumab
- Pemetrexed, Carboplatin
- Etoposide, Carboplatin
- Docetaxel
610
Endpoints
16.8%
% Stage III unresectable NSCLC*
42%
Average % PD-L1 tested
*NSCLC: Non-Small Cell Lung Carcinoma
Note that the estimated patient counts provided (prior to inclusion/exclusion criteria) are specific to our Belgian dataset. The LynxCare datasets continue to expand, encompassing real-world data from hospitals across Europe. Complete the request feasibility form linked above to discuss your study needs with one of our RWE experts.
Closing the Gap
The Value of Unstructured Data in the Lung Cancer Pathway
Structured vs. Unstructured
Structured data alone only provides part of the picture, missing key nuances. Combining structured data with rich EHR narrative data can improve our understanding of lung cancer pathophysiology, outcomes and characteristics at diagnosis, as evidenced by our data which yielded a higher prevalence of COPD patients of 19.6% vs 12.5% on structured data only.
RCT vs RWD
During the year following U.S. regulatory approval of PD‐1 inhibitors for treatment of NSCLC, real‐world patients receiving nivolumab or pembrolizumab were older at treatment initiation and more had smoking history relative to clinical trial cohorts. Studies of outcomes in underrepresented subgroups are needed to inform real‐world treatment decisions.
Real-World Insights into the Patient Journey
By leveraging unstructured data, we can obtain a more comprehensive and accurate view of the patient journey, enabling better decision-making and improved patient care.
Unpacking The Data
The Sources Behind Our Insights
How Pharma Can Leverage LynxCare's Dataset
Clinical Trial Design
Our granular and quality-controlled real-world dataset can help design clinical trials that better reflect real-world scenarios.
Synthetic Control Arm
Our dataset can be used to create synthetic control arms, which can be used to evaluate the effectiveness of new treatments.
Market Access
Our dataset can help pharma companies gain a better understanding of the market and generate granular value dossiers for HEOR.
Medical Affairs
Our dataset can help medical affairs teams better understand the clinical outcomes and real-world evidence associated with their products.
How Hospitals Can Benefit from a LynxCare Database
Improving Patient Care
Find more relevant medical information thanks to LynxCare's disease-specific NLP pipeline for a better patient and population understanding.
Research & Network Opportunities
Initiate or participate in national and international multi-center, multi-country RWE studies.
Benefit from network of KOLs.
Scientific Research
Initiate or participate in (pharma- or physician initiated) peer-reviewed (multi-center, multi-country) publications
Increased Clinical Trial Participation
More effective patients/cohort selection through clinical NLP, enrolling more patients in clinical trials
Improve your Data Quality
Receive feedback on the clinical data quality of your hospital’s database.
Benefit from data science training provided
World-Class Expertise.
The LynxCare Advantage
Differentiating factors from other NLP providers & established RWD vendors
Building Trust
Quality Control and Data Freshness
Quality Control
Data Freshness
OMOP CDM Data Warehouse
Patient Insights
More Than Numbers
Individualized Care
Cross-Disciplinary Collaboration
Impact on Patient Outcomes
The Future of Lung Cancer Therapy
How LynxCare Can Help
Personalized Medicine
With our comprehensive dataset and world-class expertise, LynxCare is well-positioned to help clinicians tailor treatments to specific patient needs, opening up the possibility of personalized medicine for lung cancer. Our data asset provides valuable insights into individual pathways of lung cancer patients, enabling clinicians to make more informed treatment decisions.
Improved Outcomes
Our data asset aims to ultimately improve patient outcomes by providing insights into the clinical pathway of lung cancer patients. By analyzing real-world patient data, our dataset offers a unique perspective on the effectiveness and safety of different treatments. This information can help clinicians make more informed treatment decisions, leading to better outcomes for patients.
Continued Innovation
LynxCare is committed to driving innovation in lung cancer treatment and management. With our world-class expertise in data analysis and interpretation, we aim to continue to provide valuable insights and solutions to healthcare providers and researchers. Our comprehensive dataset offers a wealth of information for life science companies and other stakeholders interested in advancing lung cancer therapy.
° LynxCare datasets concern datasets within the LynxCare's European hospital network. The hospitals are the data controllers. No commitment before site approval on RWE request.
